GLPBio

PU 23

Catalog No.: GC50595Purity:>98.00%
COASDSData Sheet
PU 23 is a kind of multidrug resistance protein 4 (MRP4) inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

PU 23
Cas No.: 817635-93-1
10mM (in 1mL DMSO)In Stock
$66.00
1
1mgIn Stock
$28.00
1
5mgIn Stock
$70.00
1
10mgIn Stock
$112.00
1
25mgIn Stock
$235.00
1
50mgIn Stock
$371.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

PU 23 is a kind of multidrug resistance protein 4 (MRP4) inhibitor[1]. MRP4 is an ATP-binding cassette (ABC) transporter, and MRP4 inhibition shows striking effects against cancer progression and drug resistance[2]. PU 23 shows high activity in improving cell sensibility to anticancer drug 6-mercaptopurine (6-MP)[1].

PU 23 (10μM; 72h) significantly inhibited the cell viability of HEK293/MRP4 cells with 6-MP. PU 23 (50μM; 2h) significantly increased the amount of 6-MP in HEK293/MRP4 cells[1].

References:

[1] Chen Y, Yuan X, Xiao Z, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening [J]. PLoS One, 2018, 13(10): e0205175.

[2] Wen J, Luo J, Huang W, et al. The pharmacological and physiological role of multidrug-resistant protein 4 [J]. The Journal of pharmacology and experimental therapeutics, 2015, 354(3): 358-375.

Protocol

Cell experiment [1]:

Cell lines

 HEK293/MRP4 cells

Preparation Method

 Stable HEK293/MRP4 cells were seeded at 5×103 cells per well into duplicate 96-well plates. The following day, PU 23 was added to a single well and then 6-mercaptopurine (6-MP) was added to one plate to give a final concentration of 15μM. After 72h incubation, cell viability was assessed using sulforhodamine B.

Reaction Conditions

 10μM; 72h

Applications

 PU 23 showed high activity with an inhibition rate of 81.71% with 6-MP and only 15.26% without 6-MP, while the inhibition of 6-MP was only 23.48%. PU 23 reduced resistance to anticancer agent 6-MP.

References:

[1] Chen Y, Yuan X, Xiao Z, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening [J]. PLoS One, 2018, 13(10): e0205175.

Product Documents

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
817635-93-1
SMILES
O=C(NC(=S)NC1=CC=C(C=C1)[S](=O)(=O)NCC1=CC=CC=C1)C1=CC=CC=C1
Molecular Formula
C21H19N3O3S2
Molecular Weight
425.52
Solubility
Soluble in DMSO
Storage
Store at -20°C
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for PU 23

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%